PCNA and cancer: The activity of the CDK–cyclin complex is frequently deregulated in cancer cells by a spectrum of mechanisms that include decreased levels of endogenous CDK inhibitors, leading to persistently elevated levels of active cyclin-CDK complexes, and thus uncontrolled cell growth9,10.